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INTRODUCTION.
The data demonstrate that p53 protects normal, healthy cells from DNA damage. More importantly, the results show that p53-mediated protection from DNA damaging agents can be enhanced. We treated normal, healthy cells with selenomethionine prior to challenge with cisplatin and found that the selenium supplementation enhanced DNA repair and improved cell survival following chemotherapy. However, cells that lacked a functional copy of p53 remained sensitive to the cisplatin treatment and had no improvement in DNA repair. Furthermore, the results identify a downstream target of p53, namely Xpc, that contributes significantly to the protective response in mouse bone marrow. Xpc is a protein responsible for recognizing DNA damage, and the data reveal that mice lacking the xpc gene had substantially greater bone marrow toxicity than normal mice.
BODY.
As reported previously, preliminary data from the proposal and early data following notification of this award was published (Fischer et. al.) . The work completed since the 2007 annual report is being assembled into a manuscript that will be submitted later this summer.
To evaluate any difference in sensitivity between xpc -/-mice and wildtype mice colorimetric MTS cell survival assays were performed (Fig. 1) . The chemical reduction of the MTS compound into formazan measures dehydrogenase activity in the cells; the production of formazan is directly proportional to the number of metabolically active cells. Bone marrow from wildtype and xpc -/-mice was harvested and cultured ex vivo in complete IMDM with IL-6 and SCF then treated with carboplatin for 2 hours. The MTS colorimetric reagent was added 72 hours following the carboplatin treatment. Cell survival following carboplatin treatment was calculated relative to the untreated cells for each genotype. Bone marrow from xpc -/-mice was significantly more sensitive to carboplatin treatment than bone marrow from wildtype mice.
Similar to the results from ex vivo cultures, xpc -/-mice were significantly more sensitive to the carboplatin regimen than wildtype mice. Xpc -/-and isogenic wildtype control mice were monitored for hematopoeitic toxicity during the carboplatin chemotherapy regimen described in Table 1 . It is important to reiterate that the xpc -/-mice were given one less dose of carboplatin than the wildtype mice. A Kaplan-Meier survival plot shows animal survival during the course of carboplatin treatement (Fig. 2) . While the wildtype mice began to recover, seven out of ten of the xpc -/-mice did not survive the treatment. Xpc -/-mice were substantially more sensitive to the carboplatin regimen than wildtype mice. Carboplatin doses were as follows: wildtype mice received 3 x 60 mg/kg and 2 x 100 mg/kg; xpc -/-mice received 3 x 60 mg/kg and 1 x 100 mg/kg.
Complete blood counts were taken once per week during the course of the treatment regimen, five days after administering each dose of carboplatin. At the latter time points the total white blood cells, platelets, hematocrit, and red blood cells are lower in the treated xpc -/-mice than the wildtype mice (Figs. 3-4 ). The CBC data shows that with the loss of xpc the entire hematopoietic system is more sensitive to DNA damage. Total white blood cells during the carboplatin chemotherapy regimen. Doses were as indicated on the x-axis. Complete blood counts were taken once per week during the treatment cycle, five days after each dose of carboplatin was administered. A. Mice treated with carboplatin (wildtype n=10, xpc -/-n=10). B. Untreated control mice (wildtype n=10, xpc -/-n=6). * p < 0.02, t test, xpc -/-treated relative to wildtype treated. Crosses denote mice that did not survive the carboplatin regimen. Hash marks represent the mean. Hematocrit during the carboplatin chemotherapy regimen. Doses were as indicated on the x-axis. Complete blood counts were taken once per week during the treatment cycle, five days after each dose of carboplatin was administered. A. Mice treated with carboplatin (wildtype n=10, xpc -/-n=10). B. Untreated control mice (wildtype n=10, xpc -/-n=6). * p < 0.008, t test, xpc -/-treated relative to wildtype treated. Crosses denote mice that did not survive the carboplatin regimen. Hash marks represent the mean.
Necropsies were performed on the animals from this cohort in an effort to identify the proximate cause of death; a summary of the results are shown in Table 1 . While the exact cause of death could not be determined, it is reasonable to conclude, based on the results of necropsy ( Table 1 ) that myelosuppression associated with hematopoietic toxicity was a significant factor. However, other contributing factors cannot be ruled, such as toxicity to the gastrointestinal tract that did not produce gross histological changes could have contributed to the reduced survival of the xpc -/-mice. While many tissues are adversely affected by carboplatin chemotherapy, several studies have shown that the primary dose-limiting tissue is bone marrow [1] . It is also plausible that because the mice were immuno-compromised they may have suffered bacterial infections causing sepsis. Table 1 . Necropsy report. Xpc -/-mice that received carboplatin chemotherapy had marked bone marrow suppression, whereas wildtype mice that received the treatment had no apparent suppression. The untreated xpc -/-animal also had mild bone marrow suppression, likely due to endogenous DNA damage. The carboplatin treated wildtype mice had mild cerebral hemorrhage, and the xpc -/-mice had mild to moderate cerebral hemorrhage.
The results of the necropsy study showed marked bone marrow suppression in treated xpc -/-mice but not in the wildtype mice. Femurs from wildtype and xpc -/-untreated and treated mice were sectioned and stained with DAPI or H&E to validate the effect of carboplatin on the bone marrow (Fig. 5) . The femurs from xpc -/-mice treated with carboplatin were markedly hypocellular. Furthermore, the femur from the xpc -/-control animal also had hypocellular morphology; this finding correlates with the necropsy data ( Xpc -/-mice, like the human XP patients, are known to have increased sensitivity to UV radiation and increased incidence of various tumor types. It is well documented that the Xpc protein functions in the damage recognition step of GGR. However, there is a dogma that says XPC contributes relatively little to cell survival Early experiments compared human cells to mouse cells; the human cells had normal GGR and the mouse cells lacked GGR [2] . The colony-forming ability after UV-radiation was similar, which led to the conclusion that GGR contributed little if at all to cell survival. Most early studies did not use isogenic, strain matched systems which to address the role of XPC in cell survival. Later studies employed isogenic fibroblasts of human or mouse origin lacking XPC or other effectors of GGR and showed that GGR contributed modestly to cell survival (2-3 fold) [2] [3] [4] . The present study is the first to examine in an isogenic system, the cell survival response of non-fibroblast primary cells in relation to GGR. The UV-mimetic agent carboplatin was used to induce bone marrow suppression. Xpc -/-mice were markedly sensitive to carboplatin in vivo.
Mice lacking normal, functional Xpc were substantially more sensitive to carboplatin chemotherapy than isogenic wildtype mice. The data from the complete blood counts reveal that the xpc -/-mice were consistently more affected by the carboplatin treatment than the wildtype mice. Furthermore, the CBC data reveal that all of the different lineages within the hematopoietic system were affected. Lymphocytes, neutrophils, monocytes, platelets, and red blood cells were consistently lower in the xpc -/-mice than the wildtype mice receiving the carboplatin.
The data also demonstrate that the untreated xpc -/-mice had significantly lower cellularity in several different cell populations (Gr-1, B220, CD4, CD8, Lin-) within the bone marrow relative to untreated wildtype mice. It is plausible that the basis for the reduced cellularity in the untreated mice is the contribution of endogenous DNA damage.
Perhaps the best indicator of the functional significance of Xpc loss in bone marrow is shown by the colony forming assays. The bone marrow from xpc -/-mice was substantially more impaired in colony forming capacity than bone marrow from wildtype mice following the carboplatin treatment. Again it is important to note that the xpc -/-mice had substantially reduced colony forming ability even after receiving one less dose of carboplatin than the wildtype mice. It is also worthwhile to note that while the difference in total bone marrow cellularity was not significantly different between the xpc -/-and wildtype groups following treatment the difference in colony forming capacity was more than 13-fold. The data from the necropsy study also shows that the xpc -/-mice were more affected by the carboplatin treatment than the wildtype mice.
Many studies have emphasized the role of p53 in DNA damage induced apoptosis. While it is true that normal p53 can induce apoptosis, this work highlights the importance of another, perhaps overlooked, role for p53, which is p53-mediated protection from DNA damage. Because XPC only has a role in GGR, it is typically overlooked as it is thought to contribute little to cell survival. This study demonstrates that XPC plays a substantial role in cell survival. At doses not lethal to wildtype mice, seventy percent of xpc -/-mice did not survive the carboplatin regimen.
KEY RESEARCH ACCOMPLISHMENTS
• Hematological data demonstrating marked sensitivity of xpc -/-mice to carboplatin chemotherapy.
• Pathological and histological data demonstrating marked sensitivity of xpc -/-mice to carboplatin chemotherapy.
• Demonstrate that contrary to previous reports XPC protein is important for cell survival in vitro and more importantly that it contributes substantially to mouse survival in vivo. "
REPORTABLE OUTCOMES
• Ph.D., Microbiology and Immunology, at Indiana University-Purdue University Indianapolis, Indianapolis, IN, Cancer major, biochemistry/molecular biology minor. 2008.
• P53 And Xpc Contribute Significantly to Cellular Protection From DNA Damage.
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• Data within the report has been submitted for publication and is currently under review.
CONCLUSION
The implication of this work for cancer therapeutics is the discovery that XPC plays a substantial role in protecting the hematopoietic system from the overwhelming DNA damage induced by carboplatin chemotherapy. The results show that myelosuppression in the xpc -/-mice was substantially greater than in the wildtype mice following carboplatin treatment, as indicated by the reduced bone marrow cellularity and reduced colony forming ability. There is an abundance of literature showing that p53 regulates the transcription of XPC and it is plausible that XPC plays a key role in the seleniummediated protection of normal cells from DNA damaging chemotherapeutics. Experiments that aim to further evaluate this possibility are described in the next section.
Furthermore, patients with certain XPC polymorphisms may have poor performance when treated with platinum agents, which induce DNA damage primarily repaired by NER. Some XPC single nucleotide polymorphisms have been characterized as having reduced repair capacity compared to the common allele. It may be the reduced repair capacity that is responsible for tumorigenesis in those patients. Furthermore, several studies have demonstrated polymorphisms that are associated with elevated risk for bladder, lung, and colon cancer [5] [6] [7] [8] . While a cancer could be more sensitive to the chemotherapy, the treatment toxicity could be equally elevated due to a polymorphism.
It is important to consider that while the majority of polymorphisms are present at low frequency in the population in general, they may be present at relatively high frequency in groups with certain types of cancer. Single nucleotide polymorphisms in XPC are probably not useful as a cancer prevention screen, but they may be useful as a therapeutic prognosticator. 
Abstract
The Xpc protein is a key DNA-damage recognition factor that is required for global genomic nucleotide excision repair (G-NER). In contrast to transcription-coupled NER (TC-NER), G-NER has been reported to contribute little if at all to cell survival after DNA damage. Previous studies were conducted using fibroblasts of human or mouse origin. Since the advent of xpc-/-mice, no study has focused on the bone marrow of these mice. We used carboplatin to induce DNA damage in xpc-/-and strain-matched wildtype mice. Using several independent methods xpc-/-bone marrow was about 10-fold more sensitive to carboplatin than the wildtype. 
Introduction
The xeroderma pitgmentosum XPC gene is defective in a subset of human patients exhibiting the cancer-prone disease xeroderma pigmentosum which results from defective nucleotide excision DNA repair (NER). XPC patients are sensitive to sunlight and UV-radiation-induced DNA damage and skin cancers. They also exhibit internal cancers with advanced age. The gene products encoded by XPC and other XP genes A-F have been characterized biochemically [1] .
Specifically, the Xpc protein is required and is rate-limiting for global-NER (G-NER). Xpc is not required nor apparently involved in transcription-coupled NER (TC-NER). Thus, studies of Xpc are good models for G-NER separate from TC-NER [1] .
Mice lacking xpc genes (xpc-/-mice) were generated some ten years ago [2] . A number of studies of carcinogenesis and mutagenesis have been conducted, consistent with the cancerprone human genetic disease discussed above [2] [3] [4] . No studies have examined bone marrow nor the cell survival response to DNA damage in xpc-/-mice.
Bone marrow is often dose-limiting in response to cancer chemotherapy drugs including carboplatin. While cell survival is a complex endpoint, the goal of chemotherapy is to sensitize cancer cells while retaining bone marrow cellularity. Agents that can protect bone marrow will be important adjuncts to chemotherapy. Presently, the cytokine GM-CSF is administered which causes proliferation of bone marrow myeloid stem/progenitor cells and thus re-populates bone marrow after chemotherapy [5] . The idea of G-NER as a protective mechanism in bone marrow or any other tissue is novel. The xpc gene protects bone marrow from carboplatin-induced DNA damage. Histochemical staining. Femurs were fixed in 10% buffered formalin overnight then paraffin embedded and thin sectioned for histological examination by a veterinary pathologist. Slides were stained with hematoxylin and eosin for morphological analysis or DAPI (4',6-diamidino-2-phenylindole) to visualize intact nuclear DNA. Slides were visualized by a Nikon HB-10101AF fluorescence microscope using a 100X objective. Digital photographs were captured.
Materials and Methods

Mice
Colony-forming assays. Bone marrow was collected from femurs, fibulas, and iliac crests. Total bone marrow cells were then added to complete methylcellulose medium consisting of IMDM liquid medium (Sigma), 20% fetal bovine serum, interleukin-6 (200 units per mL), and stem cell factor 100 ng per mL (Stem Cell Technologies, Vancouver, Canada). Triplicate 35mm culture dishes were seeded with 10 5 cells and placed in a humidified incubator at 37°C for 10 days at which time colonies were counted manually as in [7] . 
MTS assay of cell viability. Bone marrow of wildtype and xpc-/-
Results
Mice of wild-type and xpc-/-genotypes were first assayed for Xpc expression and global NER activity. Bone marrow was used directly for western blotting using an Xpc antibody. Bone marrow was additionally cultured 24 hrs, UV-irradiated, then subjected to an immunoassay for removal of DNA damage. Removal of DNA damage was 80% complete in wildtype mice after 16 hrs, while xpc-/-mice were completely defective in removal of the lesions (Fig. 1) . Thus, the xpc-/-mice exhibit the expected defective NER phenotype.
Twenty mice of each genotype were divided into treatment groups and administered carboplatin at weekly intervals. Mice were 10 weeks old at the time of initiating the experiment.
By day 41 of carboplatin regimen, 12/20 xpc-/-mice had died unexpectedly. No deaths were observed in wild-type mice (results not shown). During the course of carboplatin treatments, peripheral white blood cell (WBC) counts were measured weekly [6] . Peripheral WBC counts in xpc-/-mice were significantly lower than in wildtype mice (results not shown). Remaining mice were sacrificed on day 41 using approved protocols. Mice were evaluated by a veterinary pathologist. The most significant pathology was marked hypocellularity in bone marrow in 10/10 mice examined, which was visibly striking in xpc-/-mice (Fig. 2, A & B) .
To quantify and further characterize the hypocellularity in xpc-/-bone marrow, we conducted colony-forming assays and cell viability assays using a vital dye. A hallmark of myeloid stem/progenitor cell populations is their colony-forming ability when placed in culture and stimulated with cytokines. Colony-forming assays of bone marrow were conducted as in [ref. 7] . The data were plotted as total colonies per femur (Fig. 3A) , as well as total colonies per 10 6 bone marrow cells (results not shown). Irrespective of the plotting method, xpc-/-mice that received carboplatin exhibited a 10-12-fold decrease in colony-forming units compared to wildtype after 10 days in culture (Fig. 3A) . We also used the vital stain thiazolyl blue to measure cell viability after 4 days in culture. An advantage of the thiazolyl blue (or MTS) method is that a wide range of carboplatin concentrations can be assayed in contrast to in vivo carboplatin treatments. Using this method, a ten-fold difference between xpc-/-and wild-type was observed consistent with the other data (Fig. 3B) . Interestingly, a modest (three-fold) but significant decrease in bone marrow cellularity was observed in xpc-/-even in mice that did not receive carboplatin treatment (Fig. 3A) . The modest decrease may be due to endogenous DNA damage which is predicted to accumulate in xpc-/-mice [8] , although the mice were only ten weeks old at the start of the experiments, and 16 weeks old at termination of the experiments.
We reasoned that the xpc-/-DNA repair defect might additionally affect the cell cycle.
The majority (80%) of bone marrow cells when freshly harvested were in the G1 phase of the phase was observed in xpc-/-compared to wildtype (Fig. 4) . A strong G2 arrest by carboplatin was observed in both genotypes, which was however more pronounced in the xpc-/-than in wildtype (Fig. 4) .
We examined several key cell cycle regulatory proteins for differences between xpc-/-and wildtype, most of which including G1 cyclins and Rb were unremarkable (results not shown). Interesting results were obtained though for the Cul4a and Cdt1 checkpoint proteins.
Cdt1 regulates the licensing of replication origins in G1 [9] [10] [11] . Ubiquitination of Cdt1 by the ubiquitin ligase Cul4a occurs after DNA damage, is an important DNA damage signaling mechanism, and causes pre-replication complexes to dissociate from chromatin [9] [10] [11] . Cul4a is auto-ubiquitinated. We purified cellular proteins on a ubiquitin-binding resin to enrich for ubiquitinated proteins. Higher-molecular weight ubiquitinated forms of Cul4a and Cdt1 were observed in wildtype that were absent in xpc-/-bone marrow (Fig. 5A) . Given evidence that the presence or absence of Xpc appeared to affect ubiquitination of Cul4a and Cdt1 in mouse bone marrow, we asked if the presence or absence of Xpc protein would affect ubiquitination of target substrates in vitro. Using a ubiquitin-conjugating HeLa S-100 extract, we titrated increasing concentrations of recombinant Xpc to the reactions. Cul4a activity was highly efficient in the S-100 extract and was not affected by the addition of exogenous Xpc (results not shown). Xpc itself was efficiently ubiquitinated by the extract, and in fact competed with Cdt1 as a substrate.
Unexpectedly, PCNA was ubiquitinated in concert with Xpc addition (Fig. 5B) . Thus, one may conclude that in an S-100 extract Cdt1 appears to be a relatively weak substrate compared to other substrates Xpc and PCNA. The relative utilization of Cul4a substrates thus appears to be altered in xpc-/-mice ( Fig. 5A ) and one can alter substrate utilization by recombinant Xpc in vitro (Fig. 5B) . We do not exclude the possible involvement of E3 ubiquitin ligases other than Cul4a.
Discussion
It has long been known that, in contrast to TC-NER, G-NER contributes little if at all to cell survival after DNA damage [12] . Early studies were conducted on fibroblasts of mouse or human origin which differed in G-NER but were non-isogenic, concluding that G-NER contributed little if at all to cell survival [12] . Later studies used isogenic fibroblasts which showed only modest (2-3 fold) differences in cell survival after DNA damage [13, 14] . The present study is the first to address G-NER and cell survival in a whole mouse and moreover is the first to examine bone marrow in xpc-/-mice. Xpc-/-mice lacking G-NER exhibited approximately tenfold greater sensitivity to carboplatin-induced DNA damage compared to strain-matched wildtype mice. The data indicate that the xpc gene and G-NER can contribute substantially to cell survival. The cell survival endpoint was biologically relevant as bone marrow myelosuppression was dose-limiting for carboplatin, consistent with other studies [15] and the majority of xpc-/-mice died during the course of the experiments.
Although it seems intuitive that mutant genotypes affecting DNA repair such as XPC would exhibit cell cycle alterations, surprisingly few studies have examined this issue. The E3 ubiquitin ligase Cul4a is a critical signaling mechanism for DNA damage, and targets DNA repair and cell cycle arrest responses to DNA damage [16] [17] [18] [19] . Both Xpc and Cdt1 are known Cul4a substrates mediating DNA repair and cell cycle arrest, respectively. In the absence of Xpc, DNA damage accumulates and cell death is one potential outcome (Figs. 1-3 ). However, xpc-/-cells that continue to proliferate may have adapted to the absence of Xpc. A mechanism suggested in this study is by attenuation of Cul4a-mediated signaling leading to decreased Cdt1 modification and therefore a bypass of G1/S cell cycle arrest (Figs. 4, 5 ).
This study is the first to report myelosuppression associated with the Xpc-defective genotype. Human patients with xeroderma pigmentosum XPC mutant alleles have not been reported to exhibit blood disorders. The patients typically develop skin cancers well prior to age 20, and develop internal cancers with aging. Similarly, xpc-/-mice develop spontaneous lung cancers at about one year of age [4] . We intentionally used mice as young as possible for the current study. Perhaps human XPC patients would exhibit myelosuppression were they to live to advanced age. On the other hand, the mice are completely null for XPC genes, while the human mutant XPC alleles probably exhibit variable penetrance.
Recent studies point to a role for Xpc in repair of endogenous DNA damage, that is, base damage owing to oxidation [8] . Consistent with the cited study, colony-forming ability of xpc-/-bone marrow was decreased compared to wildtype even in the absence of exogenous DNA damage (i.e. carboplatin; Fig. 3A ). As base damage is removed by the separate base-excision DNA repair pathway (BER), it is conceivable that Xpc might play a role in signaling base damage. A catalytic role for Xpc in BER was suggested by the finding that Xpc enhanced the activity of the DNA glycosylase OGG1 [8] . It is likely that endogenous base damage is responsible for the late (one year) onset of lung cancers in xpc-/-mice, and may contribute to the accruement of mutagenic damage in human XPC patients as well. Here, we find a possible contribution of endogenous base damage to bone marrow cellularity. to gate the BrdU-labeled population, which were then assayed for propidium iodide content.
Values for carboplatin-treated bone marrow were divided by values for untreated bone marrow conducted side by side. The data represent three pooled mice of each genotype, assayed in two separate experiments. A modest but significant decrease in G1 population was observed in xpc-/-mice compared to wildtype mice (P < 0.05 by t-test). 
